Adamis Pharmaceuticals (Nasdaq: ADMP) announced the results of its pharmacokinetic (PK) study for its beclomethasone dipropionate HFA product, APC-1000. The ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE